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ABSTRACT
The Swedish database on notifiable communicable diseases was used to identify 24 803 cases of travel-
associated non-typhoidal salmonellosis from the period 1997–2003. Serotype data were available for
24 358 (98.2%) of these cases, which were compared with a data set from the same period of 16 255
randomly selected Swedish residents with a history of recent overnight travel outside Sweden. The
highest risk of disease was seen in travellers returning from East Africa (471 ⁄ 100 000 travellers; 95% CI
294–755), or the Indian subcontinent (474 ⁄ 100 000; 95% CI 330–681). Children aged 0–6 years were at
higher risk than travellers of other ages (OR 2.4; 95% CI 2.1–2.8). Some distinct seasonal patterns could
be distinguished, with highest (adjusted) risk in December in East Asia, and in August in Europe.
Marked geographical differences in serotype distribution were noted. Salmonella Enteritidis was
especially dominant in Europe, but was much less common in Africa, Asia and America, where the
variety of circulating serotypes was greater. Overall, the two data sets provided important information
on travel risks which are also likely to apply to travellers from other western countries.
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INTRODUCTION
International travel has grown vastly in the last
few decades. Approximately 80 million people
travel each year to Africa, Asia, the Pacific
Islands, Latin America and remote areas of
eastern Europe [1]. One downside of this inter-
connected ‘global village’ is an increasing risk of
contracting infectious diseases, especially gas-
trointestinal disease [2]. Infections caused by
Salmonella spp., as well as infections caused by
enterotoxigenic Escherichia coli (ETEC), Campylo-
bacter spp. and Shigella, are a major cause of
travellers’ diarrhoea [3–6]. Using the Kauffman–
White criteria for antisera reaction to different
bacterial O and H antigens, more than 2500
Salmonella serovars associated with non-typhoi-
dal salmonellosis (all serotypes of Salmonella
enterica except Salmonella serovar Typhi and
Salmonella serovar Paratyphi) have been identi-
fied [4]. In the developed world, salmonellosis is
associated most often with consumption of
poultry and eggs [5,6]. The infective dose is
usually high, but the bacteria grow well in most
foodstuffs. Susceptibility to infection varies, with
a lower critical infective dose in infants, as
well as elderly or compromised hosts [7].
No vaccine is available for non-typhoidal sal-
monellosis.
Surveillance statistics on travel-related infec-
tions, without denominator data on travel, will
largely reflect the travelling pattern, rather than
the risk of disease in different countries. This
report therefore used notification data and a
unique database on travel patterns to give a
detailed estimate of the risk of contracting these
diseases in various regions of the world, and to
investigate the serotype epidemiology in return-
ing travellers from various countries.
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PATIENTS AND METHODS
Notification data on salmonellosis
Salmonellosis is a notifiable disease in Sweden and is reported
to the Swedish Institute for Infectious Disease Control (SMI)
both by the physician caring for the patient (clinical notifica-
tion) and by the laboratory that diagnoses the causative agent
(laboratory notification). Clinical and laboratory reports for
each patient are merged at the SMI, using a unique personal
identification number. Newly arrived immigrants and refu-
gees can be identified from this number. The clinical notifica-
tions also include information of epidemiological relevance,
such as route of infection, risk group, and the likely place and
country of infection.
For this study, notification data for the period January
1997 to December 2003 were used. All records in the
national surveillance database concerning notified patients
with non-typhoidal salmonellosis were retrieved. Patients
with stated domestically-acquired infection, or patients for
whom information on the likely country of infection was
either missing or ‘unknown’ were excluded. The data set
was also ‘cleansed’ of infections involving recently arrived
immigrants and refugees.
Denominator data on travel patterns (the Tourist Database)
As a denominator for travel patterns, a commercial database,
the Swedish Travel and Tourist Database (TDB) was used [7].
This data set is based on a randomised selection of 2000
members of the Swedish population who are interviewed by
telephone each month with questions regarding all (business
and pleasure) recent (previous month) travel. The data are
then weighted and extrapolated to give an estimate of the total
number of Swedish travellers. From the total database,
containing data from almost 170 000 interviews, 16 255 records
from respondents with a history of recent overnight travel
outside Sweden were extracted. Data on the principal coun-
try ⁄ geographical area of travel, age and gender, and month of
travel were used for analysis. No data on any illness are
available from this data set. For this study, both the actual
number of respondents with a travel history abroad and the
extrapolated total numbers of travellers were used.
Serotyping
All isolates of Salmonella from Swedish microbiology labora-
tories are sent to the SMI for serotyping. Serotyping of
the isolates was performed by agglutination using antiserum
from Reagensia (Stockholm, Sweden). Interpretation of sero-
types was made according to the latest edition of the
Kauffman–White scheme from the WHO international refer-
ence laboratory [8].
Statistical methods
The risk of disease per 100 000 travellers was calculated using
notification data on the single diseases as the numerator, and
the estimated total numbers of travellers from the TDB as the
denominator. The actual number of individuals interviewed
was used to calculate 95% confidence intervals (95% CI) for
the estimates.
Odds ratios (OR) with corresponding 95% CI were
calculated to assess the risk factors (age, gender, month
and travel destination) for being notified with disease. The
respondents in the TDB were used as controls (with the
lowest incidence in each category used as the reference). To
adjust for confounding and test for interaction, a logistic
regression model was used, which included as variables the
country ⁄ area of destination, age, gender and month. For
each region, the OR for disease ⁄month were analysed,
adjusted for age, gender, and number of cases ⁄ travellers.
All analyses were made using the Stata 6.0 software (Stata
Corporation, College Station, TX, USA).
Ethical considerations
The TDB contains aggregated data only. Notification data is
regulated by the Swedish Communicable Disease Act, and
contains full personal identification. The subset of the notifi-
cation database extracted for this study did not contain any
information that could be linked to a specific person. The study
was approved by the Medical Ethics Committee of the
Karolinska Institute, Stockholm, Sweden.
RESULTS
Travel pattern
The 16 255 respondents in the TDB with over-
night travel to different regions during the study
period 1997–2003 formed the basis for the esti-
mates of travel to different regions. The travel
histories from the respondents were weighted
and projected to give an estimate of the number of
journeys (Table 1). According to these estimates,
Swedish travellers made c.68 million overnight
journeys to the different countries ⁄ regions (78%
leisure trips and 22% business trips) during the
period of the study.
Salmonella notifications
During the study period, notification of 31 679
patients with salmonellosis was received
(Table 2). Most of these infections (24 803; 78%)
were travel-associated, with cases associated with
travel to 151 different countries. The total number
of notified travel-associated cases of salmonellosis
from single countries mainly reflected the travel
pattern of Swedes and, to a lesser extent, the risk
of disease in the various countries (Table 1). The
ten countries stated most often as the country of
infection were, in descending order, Spain
(n = 6156), Thailand (n = 4594), Greece
(n = 1885), Turkey (n = 1391), Tunisia (n = 733),
Poland (n = 657), Morocco (n = 643), Portugal
(n = 605), Cyprus (n = 560) and Indonesia
(n = 525).
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Risk factors
The overall risk of being notified with salmonel-
losis was 36.5 ⁄ 100 000 travellers. The lowest risk
was seen in the Nordic countries (1.7 ⁄ 100 000
travellers); this region was therefore used as the
reference in the further logistic regression model,
where the relative risks for various countries were
adjusted for age, gender, and month of travel. The
highest individual risk was seen in developing
countries, specifically East Africa (OR 405;
95% CI 249–658), India and neighbouring coun-
tries (OR 310; 95% CI 212–453), East Asia (OR
198; 95% CI 172–228), and West Africa (OR 176;
95% CI 112–277). The risk decreased with increas-
ing age. Gender was not associated with a higher
risk of being notified with salmonellosis (Table 1).
Serotype distribution
Of the 24 803 episodes of travel-associated salmo-
nellosis, serotype data were available for 24 358
(98.2%) episodes. In total, 202 different serotypes
Table 1 Estimated number of trav-
ellers, respondents in the Swedish
Travel and Tourist Database (con-
trols) and notified cases with
travel-associated non-typhoidal sal-
monellosis (1997–2003), with an un-
adjusted risk estimate ⁄ 100 000 and
multivariate odds ratios from a
logistic regression model adjusted
for the risk factors of age, gender,









100 000 95% CI
Multivariate
odds ratio 95% CI
Total 67 870 000 16 255 24 803 36.5 35.8–37.3 – –
0–6 years 3 300 000 524 1763 53.4 48.5–58.9 2.3 2.0–2.7
7–18 years 8 150 000 1599 2933 36.0 33.9–38.2 1.4 1.2–1.6
19–45 years 30 520 000 6708 10 942 35.9 34.8–37.0 1.2 1.1–1.3
46–65 years 21 850 000 5990 7728 35.4 34.2–36.6 1.0 0.9–1.1
>65 years 4 050 000 1434 1441 35.6 33.1–38.3 1.0 Reference
Men 36 020 000 8145 12 357 34.3 33.4–35.3 1.1 1.0–1.1
Women 31 850 000 8110 12 446 39.1 38.0–40.2 1.0 Reference
Nordic countries 22 730 000 5350 397 1.7 1.6–1.9 1.0 Reference
Western Europe 14 800 000 3584 1119 7.6 7.1–7.8 4.6 4.1–5.2
Southern Europe 12 070 000 2931 7202 59.7 57.2–62.3 38.2 34.1–42.8
Eastern Europe 3 320 000 818 1945 58.6 54.0–63.6 32.2 28.2–36.8
(incl. Baltic Republics)
Eastern Mediterranean 7 740 000 1817 4185 54.1 51.2–57.1 27.7 24.6–31.2
Russia and former USSR 260 000 59 100 38.5 27.9–53.1 24.7 17.5–34.8
Arabian countries and Iran 220 000 44 282 128 93–176 71.5 50.9–100.4
India with neighbours 120 000 31 569 474 330–681 310 212–453
East Asia 2 050 000 517 5535 270 247–295 198 172–228
Australia, New Zealand
and the Pacific
450 000 116 46 10.2 7.3–14.4 6.9 4.8–9.9
North Africa 770 000 196 1794 233 201–271 151 126–181
West Africa 80 000 22 223 279 180–432 176 112–276
East Africa 90 000 18 424 471 294–755 405 249–658
Central Africa 30 000 8 28 93.3 42.5–204.8 47.0 21.1–104.8
Southern Africa 170 000 42 117 68.8 48.4–97.9 50.0 34.5–72.5
North America 2 170 000 503 55 2.5 1.9–3.3 1.7 1.2–2.3
Central America 170 000 43 183 108 77–150 70.0 49.2–99.5
Caribbean 380 000 95 408 107 86–134 73.1 57.0–93.9
South America 250 000 61 199 79.6 59.7–106.0 59.9 43.9–81.6
aNordic countries: Denmark, Finland, Iceland, Norway; Western Europe: Austria, Belgium, France, Germany,
Ireland, Luxembourg, the Netherlands, Switzerland, UK; Southern Europe: Italy, Malta, Monaco, Portugal, Spain;
Eastern Europe: Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia; Eastern
Mediterranean: Albania, Cyprus, former Yugoslavia, Greece, Israel, Turkey; Russia and former USSR: Armenia,
Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan;
Arabian countries and Iran: Bahrain, Iraq, Iran, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, United
Arab Emirates, Yemen; India with neighbours: Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan,
Sri Lanka; East Asia: Brunei, Burma, Cambodia, China, Hong Kong, Indonesia, Japan, Laos, Malaysia, Mongolia,
North Korea, Philippines, South Korea, Singapore, Taiwan, Thailand, Tibet, Vietnam; Australia: New Zealand and
the Pacific, American Samoa, Australia, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, Marshall Islands,
Micronesia, Nauru, New Caledonia, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Tokelau, Tonga,
Tuvalu, Vanuatu, Wallis and Futuna; North Africa: Algeria, Egypt, Libya, Morocco, Tunisia; West Africa: Benin,
Burkina Faso, Cape Verde, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Senegal, Sierra
Leone, The Gambia, Togo; East Africa: Burundi, Djibouti, Eritrea, Ethiopia, Kenya, Rwanda, Seychelles, Somalia,
Sudan, Tanzania, Uganda; Central Africa:, Cameroon, Central African Republic, Chad, Congo Brazzaville,
Equatorial Guinea, Gabon, Niger, Nigeria, Republic of Congo, Sa˜o Tome´ et Principe; Southern Africa: Angola,
Botswana, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, South Africa, Zambia, Zimbabwe;
North America: Canada, USA; Central America: Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico,
Nicaragua, Panama; Caribbean: Antigua and Barbuda, Bahamas, Barbados, Bermuda, Cayman Islands, Cuba,
Dominica, Dominican Republic, Grenada, Guadeloupe, Jamaica, Haiti, Martinique, Netherlands Antilles, Puerto
Rico, St. Christopher and Nevis, St. Lucia ⁄ St. Vincent, St. Kitts-Nevis, The Grenadines, Trinidad and Tobago, Virgin
Islands; South America: Bolivia, Brazil, Colombia, Ecuador, French Guiana, Guyana, Honduras, Paraguay, Peru,
Suriname, Uruguay, Venezuela.
Table 2. Notified cases of non-typhoidal salmonellosis in
Sweden (1997–2003)
Disease and
category of infection 1997 1998 1999 2000 2001 2002 2003 1997–2003
Infected in Sweden 595 453 947 678 671 818 805 4967
Travel-associated 3569 3829 3923 3893 3819 2930 2840 24 803
Immigrants ⁄ refugees 81 77 40 42 8 9 10 267
Unknown 455 235 231 235 214 133 139 1642
Total 4700 4594 5141 4848 4712 3890 3794 31 679
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were represented among the notified cases during
the period. Distinct regional variations in serotype
distribution were noted (Table 3). Although it was
the most common serotype in most regions of the
world, Salmonella Enteritidis was especially dom-
inant in Europe, where more than two-thirds of all
cases of salmonellosis were caused by this sero-
type. In Africa, Asia and America, this serotype
was far less dominant, and the variety of other
circulating serotypes was greater.
Seasonality
The seasonal pattern varied between different
regions of the world. In most regions, the number
of cases was too small for a detailed analysis of
seasonality. Therefore, the analysis concentrated
on: (i) the Nordic countries and western Europe
(1516 cases); (ii) the Mediterranean region, inclu-
ding southern Europe, eastern Mediterranean and
North Africa (13 181 cases); and (iii) East Asia
(5535 cases). The adjusted ORs for Salmonella
infection ⁄month in these three regions are shown
in Fig. 1. Some distinct seasonal patterns could
be distinguished, with the highest risks existing
during June–September in Europe, and in
November–December in East Asia. The seasonal-
ity was more marked in northern ⁄western Europe
than in the Mediterranean region.
DISCUSSION
Reliable denominator data on travel are essential
for calculating the risks of travel-related disease in
various parts of the world [9]. In most countries,
travel statistics are based on official figures for the
first destination of international air travel. Since
many Swedish long-distance passengers change
flights in the large airports at Copenhagen,
Frankfurt, Amsterdam, London and Paris, the
official statistics overestimate travel to these
countries and greatly underestimate travel to
subsequent destinations in Africa, Asia and South
America.
In contrast, the TDB gives information on each
country ⁄ region visited for at least one overnight
stay. This provides a unique opportunity to relate
surveillance data to a more appropriate travel
denominator, as has been done previously for
dengue fever [10] and rickettsiosis [11].
The data presented in this study concern
Swedish travellers, and the travel patterns of
Table 3. Serotype distribution of the ten most common
Salmonella serotypes ⁄ region (1997–2003)
Region ⁄ serotype Distribution (n, %)
Nordic countries (n = 389)
S. Enteritidis 249 (64.0)
S. Typhimurium 68 (16.5)
S. Infantis 16 (4.1)
S. Virchow 5 (1.3)
S. Hadar 4 (1.0)
S. Oranienburg 4 (1.0)
S. Newport 3 (0.8)
S. Stanley 3 (0.8)
S. Agona 2 (0.5)
S. Saintpaul 2 (0.5)
Others (n = 21) 33 (8.5)
Western Europe (n = 1099)
S. Enteritidis 826 (75.2)
S. Typhimurium 116 (10.6)
S. Virchow 15 (1.4)
S. Hadar 12 (1.1)
S. Infantis 9 (0.8)
S. Newport 6 (0.5)
S. Blockley 6 (0.5)
S. Braenderup 6 (0.5)
S. Indiana 6 (0.5)
S. Heidelberg 4 (0.4)
Others (n = 35) 93 (8.5)
Southern Europe (n = 7089)
S. Enteritidis 5616 (79.2)
S. Typhimurium 564 (8.0)
S. Hadar 115 (1.6)
S. Virchow 87 (1.2)
S. Newport 41 (0.6)
S. Infantis 29 (0.4)
S. Heidelberg 22 (0.3)
S. Montevideo 16 (0.2)
S. Braenderup 14 (0.2)
S. Muenchen 14 (0.2)
Others (n = 75) 571 (8.1)
Eastern Europe (n = 1881)
S. Enteritidis 1467 (78.0)
S. Typhimurium 148 (7.9)
S. Hadar 73 (3.9)
S. Saintpaul 23 (1.2)
S. Infantis 21 (1.1)
S. Agona 18 (1.0)
S. Virchow 9 (0.5)
S. Blockley 7 (0.4)
S. Derby 7 (0.4)
S. Corvallis 6 (0.3)
Others (n = 37) 102 ()
Eastern Mediterranean (n = 4096)
S. Enteritidis 2425 (59.2)
S. Typhimurium 319 (7.8)
S. Virchow 294 (7.1)
S. Agona 107 (2.6)
S. Hadar 96 (2.3)
S. Infantis 47 (1.1)
S. Oranienburg 45 (1.1)
S. Montevideo 40 (1.0)
S. Mbandaka 33 (0.8)
S. Anatum 22 (0.5)
Others (n = 79) 1422 (34.7)
Russia and former USSR (n = 98)
S. Enteritidis 71 (72)
S. Typhimurium 10 (10)
S. Kottbus 4 (4)
S. Muenchen 2 (2)
S. Hadar 1 (1)
S. Agona 1 (1)
S. Bareilly 1 (1)
S. Isangi 1 (1)
S. London 1 (1)
S. Virchow 1 (1)
Others (n = 4) 4 (4)
Arabian countries and Iran (n = 275)
S. Enteritidis 61 (22.2)
S. Typhimurium 44 (16.0)
S. Agona 16 (5.8)
S. Infantis 15 (5.5)
(continued)
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Table 3. Continued
Region ⁄ serotype Distribution (n, %)
S. Blockley 13 (4.7)
S. Montevideo 9 (3.3)
S. Newport 6 (2.2)
S. Mbandaka 5 (1.8)
S. Oranienburg 4 (1.5)
S. Anatum 3 (1.1)
Others (n = 44) 99 (36.0)
India and neighbours (n = 560)
S. Typhimurium 68 (12.1)
S. Enteritidis 67 (12.0)
S. Bareilly 66 (11.8)
S. Virchow 58 (10.4)
S. Braenderup 45 (8.0)
S. Newport 22 (3.9)
S. Oslo 21 (3.8)
S. Stanley 18 (3.2)
S. Mbandaka 17 (3.0)
S. Worthington 12 (2.1)
Others (n = 40) 166 (29.6)
East Asia (n = 5463)
S. Enteritidis 826 (15.1)
S. Stanley 609 (11.1)
S. Hadar 470 (8.6)
S. Virchow 403 (7.4)
S. Panama 293 (5.4)
S. Newport 195 (3.6)
S. Agona 165 (3.0)
S. Typhimurium 144 (2.6)
S. Java 132 (2.4)
S. Rissen 131 (2.4)
Others (n = 86) 2095 (38.3)
Australia, New Zealand, Pacifics (n = 45)
S. Enteritidis 11 (24)
S. Hadar 6 (13)
S. Typhimurium 6 (13)
S. Oranienburg 4 (9)
S. Virchow 3 (7)
S. Brandenburg 2 (4)
S. Java 2 (4)
S. Javiana 2 (4)
S. Panama 2 (4)
S. Thompson 2 (4)
Others (n = 5) 5 (11)
North Africa (n = 1755)
S. Enteritidis 600 (34.2)
S. Typhimurium 178 (10.1)
S. Hadar 131 (7.5)
S. Virchow 97 (5.6)
S. Braenderup 60 (34.2)
S. Blockley 52 (3.0)
S. Infantis 48 (2.7)
S. Haifa 42 (2.4)
S. Anatum 41 (2.4)
S. Livingstone 34 (1.9)
Others (n = 57) 472 (26.9)
West Africa (n = 220)
S. Virchow 44 (20.0)
S. Stanleyville 21 (9.5)
S. Enteritidis 14 (6.4)
S. Hull 13 (5.9)
S. Typhimurium 9 (4.1)
S. Chester 6 (2.7)
S. Mbao 4 (1.8)
S. Grumpenisis 4 (1.8)
S. Oranienburg 4 (1.8)
S. Tyresoe 4 (1.8)
Others (n = 57) 97 (44.1)
Central Africa (n = 26)
S. Colindale 3 (12)
S. Enteritidis 2 (8)
S. Chester 2 (8)
S. Coeln 1 (4)
S. Hadar 1 (4)
S. Heidelberg 1 (4)
S. Infantis 1 (4)
S. Plymouth 1 (4)
S. Stanleyville 1 (4)
S. Typhimurium 1 (4)
Table 3. Continued
Region ⁄ serotype Distribution (n, %)
Others (n = 12) 12 (5)
East Africa (n = 415)
S. Enteritidis 92 (22.2)
S. Typhimurium 33 (8.0)
S. Heidelberg 32 (7.7)
S. Newport 28 (67.5)
S. Braenderup 27 (6.5)
S. Virchow 16 (3.9)
S. Agona 12 (2.9)
S. Hadar 12 (2.9)
S. Oranienburg 11 (2.7)
S. Haifa 9 (2.2)
Others (n = 61) 143 (34.5)
Southern Africa (n = 114)
S. Enteritidis 20 (17.5)
S. Typhimurium 20 (17.5)
S. Virchow 11 (9.6)
S. Muenchen 7 (6.1)
S. Braenderup 3 (2.6)
S. Heidelberg 3 (2.6)
S. Infantis 3 (2.6)
S. Newport 3 (2.6)
S. Agona 2 (1.7)
S. Isangi 2 (1.7)
Others (n = 29) 40 (35.1)
North America (n = 54)
S. Typhimurium 16 (29)
S. Enteritidis 6 (11)
S. Newport 4 (7)
S. Heidelberg 3 (6)
S. Javiana 3 (6)
S. Agona 2 (4)
S. Litchfield 2 (4)
S. Schwarzengrund 2 (4)
S. Hadar 2 (4)
S. Infantis 1 (2)
Others (n = 13) 13 (24)
Central America (n = 179)
S. Agona 28 (15.6)
S. Enteritidis 24 (13.4)
S. Typhimurium 18 (10.1)
S. Infantis 15 (8.4)
S. Panama 11 (6.1)
S. Javiana 6 (3.4)
S. Newport 6 (3.4)
S. Sandiego 5 (2.8)
S. Braenderup 4 (2.2)
S. Heidelberg 4 (2.2)
Others (n = 26) 58 (32.4)
Caribbean (n = 402)
S. Enteritidis 223 (55.5)
S. Typhimurium 28 (7.0)
S. Infantis 19 (4.7)
S. Agona 12 (3.0)
S. Newport 9 (2.2)
S. Senftenberg 7 (1.7)
S. Braenderup 6 (1.5)
S. Heidelberg 6 (1.5)
S. Derby 5 (1.2)
S. Uganda 5 (1.2)
Others (n = 31) 76 (18.9)
South America (n = 198)
S. Enteritidis 45 (22.7)
S. Saintpaul 39 (19.7)
S. Newport 22 (11.1)
S. Agona 7 (3.5)
S. Infantis 5 (2.5)
S. Javiana 5 (2.5)
S. Albany 4 (2.0)
S. Heidelberg 4 (2.0)
S. Montevideo 4 (2.0)
S. Typhimurium 4 (2.0)
Others (n = 32) 58 (29.3)
142 Clinical Microbiology and Infection, Volume 11 Number 2, February 2005
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 138–144
individuals from other western countries may
differ from those of Swedes. However, since the
results have been adjusted for age, gender, and
month of travel, and the estimates of risk are
related to the number of Swedes travelling to
different countries, the main conclusions should
also be valid for travellers from other western
countries to those areas for which there is enough
statistical power to detect elevated risks.
No data on travel-related illnesses in the con-
trols were available from the TDB, so the possi-
bility that the control group could also have
included individuals who had experienced dis-
ease during their travel cannot be excluded.
However, all calculations were based on the odds
of being notified in Sweden after returning home,
and not on the odds of falling ill (for which no
data were available). Considering the small num-
ber of notified cases and controls in relation to the
total estimated number of travellers, it would be
unlikely that any single person would be included
both as a patient and as a control.
In most countries, as in Sweden, official data on
travel-related infections give the number of
infections ⁄ country, without relating these figures
to travel statistics. In this way, the figures are
better suited to reflect travel patterns than to give
useful information on the risk of contracting
disease in various regions of the world. Therefore,
the data from the present study better reflect the
relative risks of contracting salmonellosis in dif-
ferent travel destinations. Since Sweden has a
uniform national system for reporting infectious
diseases, and the notification database is based on
both clinical and laboratory notifications, the
sensitivity of the notification system is comparat-
ively good. Using the capture-recapture technique
[12] to estimate the proportion of cases being
reported by either clinicians or laborator-
ies, >99% of all diagnosed Salmonella infections
were reported each year during the period 1998–
2002 [13]. However, notification data only repre-
sent a small minority of all diseases experienced
by travellers. Salmonellosis is an acute, usually
self-limited disease. Most cases are never atten-
ded by a physician, and even fewer are investi-
gated microbiologically after return to Sweden.
The actual number of individuals infected by
Salmonella is likely to be more than ten-fold the
number presented here.
The study design only allowed for detection of
cases diagnosed after return to Sweden. The
notification data should therefore reflect what
happened during the last week of stay in each
respective country. If, as suggested previously,
the risk of travellers’ diarrhoea is higher during
the first 2 weeks in a highly endemic area [1, 14],
the calculated risks may be underestimated in
travel destinations involving a more prolonged
stay. However, individuals staying for long peri-
ods abroad are also less likely to be interviewed
by telephone in Sweden, thereby compensating
for the missed cases.
In the present study, certain regions of the
world stood out as special high-risk areas for
contracting salmonellosis. These areas include
East Africa and the Indian subcontinent, consis-
tent with previous reports on traveller’s diarrhoea
[15,16,], and also East Asia. Large variations in
odds ratios were seen within the African contin-
ent. Although based on small numbers, these
differences were significant, and the reasons for
these variations require further investigation.
Trips to neighbouring countries also pose some
risk. Very rigorous control methods mean that
Sweden has an extremely low domestic incidence
of salmonellosis [17,18]. At least 75% of all
notified episodes of salmonellosis in Sweden are
travel-related. Even in neighbouring Denmark,
the situation is reversed, with only 25% of cases
involving the most common serotype, Salmonella


















Fig. 1. Seasonal pattern of notified cases of travel-
associated non-typhoidal salmonellosis (1997–2003). The
monthly odds ratios (OR) for Salmonella notifications are
adjusted for age, gender and number of travellers in a
multivariate logistic regression model. The OR should be
interpreted as the relative risk compared with the month
with the lowest risk, estimated for each region separately
(a theoretical region with the same risk each month would
then have OR of 1.0 for each month – regardless of the
number of cases).
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further decrease the incidence of salmonellosis in
Swedish residents should therefore focus on
imported food and on travel advice, including
close destinations.
Young age was a significant risk factor for
salmonellosis, with the individual risk decreasing
with increasing age. It has been suggested previ-
ously [6] that the elevated risk in the youngest
part of the population is associated with increased
faecal ⁄ oral contamination and decreased immu-
nity, and that the high risk in young adults is
associated with ingestion of larger volumes of
potentially contaminated food and an adventur-
ous lifestyle.
The study showed large variations in serotype
distribution between different regions. Salmonella
Enteritidis, which is often associated with egg and
poultry consumption [8,9], was among the most
common serotypes in all regions, but was most
dominant in Europe (c.70% of cases compared
with only 11% of cases in North America).
Serotypes were much more heterogenous in
tropical countries than in temperate regions,
indicating the higher impact of a local flora, and
probably also reflecting a less-developed food
distribution system over large geographical areas.
Since the seasonal distribution of ORs for disease
was adjusted for age, gender and the number of
travellers, the differing seasonal patterns between
the regions should reflect a true seasonality of the
disease risk. However, an alternative explanation
could be that travellers with different risk behav-
iours visit these regions at different times of the
year.
Overall, the present study demonstrated that
crude data regarding the country of notified infec-
tion are less-suited to predict the risk of disease in
various travel destinations. In order to be useful,
the data should be related to a travel denominator.
Such denominator-based information could form
the basis for pre-travel advice. In addition to
patients at medical risk, groups that are especially
likely to benefit from such advice are young people
and parents of small children travelling to Africa
and to the Indian subcontinent.
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